Avid Bioservices Inc (CDMO)

[cjgaddy]

5-9-18: New Bavi+Keytruda/HCC Ph2 Trial hits ClinicalTrials. Sponsor=UTSW, Collaborator=MERCK
“A Phase II Study of Pembrolizumab(Keytruda) + Bavituximab in Patients with Advanced Hepatocellular [Liver] Carcinoma”
https://clinicaltrials.gov/ct2/show/NCT03519997
BRIEF SUMMARY:
This is a non-randomized, open-label, multi-site Phase II therapeutic trial of pembrolizumab(Merck’s Keytruda, Anti-PD-1) & bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.
SPONSOR: UTSW-MC/Dallas
COLLABORATOR: Merck Sharp & Dohme Corp.
First Posted: May 9 2018; Status: Recruiting
Actual Study Start Date: April 26 2018
Est. N=34
PI: Muhammad Beg, MD, UTSW-MC http://profiles.utsouthwestern.edu/profile/125541/muhammad-beg.html
HCC = Hepatocellular Carcinoma, a primary malignancy of the Liver